Page 4 - While Enzolytics Inc News Today

(1) COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," [https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics-whitepaper.html] highlights Intels Artificial Intelligence Analytic tools and Enzolytics innovative approac...

Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good ACCESSWIRE 17 May 2021, 21:05 GMT+10 COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, Optimizing Empathetic A.I. to Cure Deadly Diseases, [https://www.intel.com/content/www/us/en/h...

COLLEGE STATION, TX / ACCESSWIRE / May 12, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has granted a distributorship license to a European pharma entity (the Licensing

(1) COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has engaged TEN Associates LLC (the "Consultant") to assist the Company in disseminating and updating meaningful, relevant and factual information about Enzolytics, and its progress in fulfilling its business strategy, to market makers, the brokerage community, individual investors, the media and the public. Since the combination with BioClonetics Immunotherapeutics, I...

Enzolytics, Inc.: Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company"). We continue to make great strides in the application of our multiple platforms for production of therapeutics for treating infectious diseases. Our future success will follow as we meet our goals to bring these therapeutics to market with new developments made possible by our extensive pla...

(0) COLLEGE STATION, TX / ACCESSWIRE / April 5, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company"). In a significant development, recent findings have revealed that the monoclonal antibodies being produced by the Company against targeted sites on the Coronavirus are directed against epitopes that exist conservatively on each of the variant strains of the virus from the UK, Brazil and South African. These findings are considered by the Company as highly significant in that the Center for...

(0) COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The agreements are with the Companys partners in IMBL formed with a group of successful Bulgarian businessmen. As a team, the Company with IMPL is moving forward to com...

Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company")

Press release content from Accesswire. The AP news staff was not involved in its creation. Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus) February 22, 2021 GMT Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company’s Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets “ENZC” or the “Company”) today announced it has identif...

(2) COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Companys ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Companys ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza medicine Tamiflu ®. Currently, the ITV-1/IPF th...